Drug · CHEMBL481
Comparisons in its trials182
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 182
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: deaths from any cause | 507 of 624 | 499 of 629 | 1,253 | NCT02753127 | Trial comparisons |
| Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: serious adverse events | 234 of 622 | 201 of 610 | 1,232 | NCT02753127 | Trial comparisons |
| Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Safety - Number of Patients Experiencing Any Adverse Event | 599 of 600 | 597 of 602 | 1,202 | NCT00154102 | Trial comparisons |
| Cetuximab Plus FOLFIRI vs FOLFIRI Alone: serious adverse events | 263 of 600 | 204 of 602 | 1,202 | NCT00154102 | Trial comparisons |
| Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Participants With No Residual Tumor After Metastatic Surgery | 29 of 599 | 10 of 599 | 1,198 | NCT00154102 | Trial comparisons |
| Arm A: FOLFOX or FOLFIRI + Bevacizumab vs Arm B: FOLFOX or FOLFIRI + Cetuximab: serious adverse events | 98 of 559 | 111 of 578 | 1,137 | NCT00265850 | Trial comparisons |
| FOLFIRI + Ramucirumab vs FOLFIRI + Placebo: serious adverse events | 198 of 529 | 175 of 528 | 1,057 | NCT01183780 | Trial comparisons |
| Panit. Plus Bevacizumab With Chemotherapy vs Bevacizumab With Chemotherapy: serious adverse events | 306 of 518 | 188 of 510 | 1,028 | NCT00115765 | Trial comparisons |
| FOLFIRI + Sunitinib vs FOLFIRI + Placebo: Number of Participants With Overall Confirmed Objective Response | 124 of 386 | 128 of 382 | 768 | NCT00457691 | Trial comparisons |
| FOLFIRI + Sunitinib vs FOLFIRI + Placebo: serious adverse events | 170 of 384 | 111 of 379 | 763 | NCT00457691 | Trial comparisons |
| NALIRIFOX vs Nab-paclitaxel+Gemcitabine: deaths from any cause | 345 of 370 | 359 of 379 | 749 | NCT04083235 | Trial comparisons |
| NALIRIFOX vs Nab-paclitaxel+Gemcitabine: serious adverse events | 207 of 370 | 198 of 379 | 749 | NCT04083235 | Trial comparisons |
| Pembrolizumab vs Chemotherapy: Number of Participants Experiencing an Adverse Event (AE) | 301 of 314 | 288 of 296 | 610 | NCT02564263 | Trial comparisons |
| Pembrolizumab vs Chemotherapy: Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE) | 40 of 314 | 42 of 296 | 610 | NCT02564263 | Trial comparisons |
| Tislelizumab vs Investigator Chosen Chemotherapy (ICC): deaths from any cause | 233 of 256 | 233 of 256 | 512 | NCT03430843 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: Disease Control Rate (DCR) | 147 of 255 | 126 of 257 | 512 | NCT03665441 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: Objective Response Rate (ORR) | 41 of 255 | 32 of 257 | 512 | NCT03665441 | Trial comparisons |
| Tisotumab Vedotin vs Chemotherapy: deaths from any cause | 123 of 253 | 140 of 249 | 502 | NCT04697628 | Trial comparisons |
| Tislelizumab vs Investigator Chosen Chemotherapy (ICC): serious adverse events | 109 of 255 | 106 of 240 | 495 | NCT03430843 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: deaths from any cause | 209 of 248 | 211 of 246 | 494 | NCT03665441 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL481/comparisons